

TOMAS OLSSON PUBLICATIONS 2015**Peer-reviewed articles**

Aeinehband S, Lindblom RPF, Al Nimer F, Vijayaraghavan S, Sandholm K, Khademi M, Olsson T, Nilsson B, Ekdahl KN, Darreh-Shori T, Piehl F. Complement Component C3 and Butyrylcholinesterase Activity Are Associated with Neurodegeneration and Clinical Disability in Multiple Sclerosis. *Plos One* 2015; 10.

Alam I, Koller DL, Canete T, Blazquez G, Mont-Cardona C, Lopez-Aumatell R, Martinez-Membrives E, Diaz-Moran S, Tobena A, Fernandez-Teruel A, Stridh P, Diez M, Olsson T, Johannesson M, Baud A, Econs MJ, Foroud T. Fine mapping of bone structure and strength QTLs in heterogeneous stock rat. *Bone* 2015; 81: 417-426.

Ambati A, Poiret T, Svahn BM, Valentini D, Khademi M, Kockum I, Lima I, Arnheim-Dahlstrom L, Lamb F, Fink K, Meng Q, Kumar A, Rane L, Olsson T, Maeurer M. Increased -haemolytic group A streptococcal M6 serotype and streptodornase B-specific cellular immune responses in Swedish narcolepsy cases. *Journal of Internal Medicine* 2015; 278: 264-276.

Axelsson M, Novakova L, Khademi M, Zetterberg H, Blennow K, Malmestrom C, Piehl F, Olsson T, Lycke J. CSF biomarker levels of inflammation and degeneration in relapsing MS following switch to fingolimod from other disease modifying therapies. *Multiple Sclerosis Journal* 2015; 21: 346-346.

Barnes D, Leist T, Freedman M, Olsson T, Miller A, Wolinsky J, O'Connor P, Benamor M, Truffinet P, Comi G. SAFETY AND TOLERABILITY OF TERIFLUNOMIDE IN CLINICAL STUDIES. *Journal of Neurology Neurosurgery and Psychiatry* 2015; 86.

Bedri SK, Fink K, Lundstrom W, Olsson T, Glaser A, Hillert J. From genetic variations to plasma cytokine receptor levels during MS treatment. *Multiple Sclerosis Journal* 2015; 21: 352-353.

Bergman P, Piket E, Khademi M, James T, Linden M, Kockum I, Brundin L, Piehl F, Olsson T, Jagodic M. Circulating miR-150 in cerebrospinal fluid is a novel biomarker for multiple sclerosis. *Multiple Sclerosis Journal* 2015; 21: 633-633.

Canto E, Tintore M, Villar LM, Costa C, Nurtdinov R, Alvarez-Cermeno JC, Arrambide G, Reverter F, Deisenhammer F, Hegen H, Khademi M, Olsson T, Tumani H, Rodriguez-Martin E, Piehl F, Bartos A, Zimova D, Kotoucova J, Kuhle J, Kappos L, Garcia-Merino JA, Sanchez AJ, Saiz A, Blanco Y, Hintzen R, Jafari N, Brassat D, Lauda F, Roesler R, Rejdak K, Papuc E, de Andres C, Rauch S, Khalil M, Enzinger C, Galimberti D, Scarpini E, Teunissen C, Sanchez A, Rovira A, Montalban X, Comabella M. Chitinase 3-like 1: prognostic biomarker in clinically isolated syndromes. *Brain* 2015; 138: 918-931.

Checa A, Khademi M, Sar DG, Haeggstrom JZ, Lundberg JO, Piehl F, Olsson T, Wheelock CE. Hexosylceramides as intrathecal markers of worsening disability in multiple sclerosis. *Multiple Sclerosis Journal* 2015; 21: 1271-1279.

Feltelius N, Persson I, Ahlqvist-Rastad J, Andersson M, Arnheim-Dahlstrom L, Bergman P, Granath F, Adori C, Hokfelt T, Kuhlmann-Berenzon S, Liljestrom P, Maeurer M, Olsson T, Ortqvist A, Partinen M, Salmonson T, Zethelius B. A coordinated cross-disciplinary research

initiative to address an increased incidence of narcolepsy following the 2009-2010 Pandemrix vaccination programme in Sweden. *Journal of Internal Medicine* 2015; 278: 335-353.

Flytzani S, Guerreiro-Cacais AO, N'Diaye M, Lindner M, Linington C, Meinl E, Stridh P, Jagodic M, Olsson T. MOG-induced experimental autoimmune encephalomyelitis in the rat species triggers anti-neurofascin antibody response that is genetically regulated. *Journal of Neuroinflammation* 2015; 12.

Flytzani S, Ortlieb AGC, Ndiaye M, Lindner M, Linington C, Meinl E, Stridh P, Jagodic M, Olsson T. MOG-induced EAE in rats triggers anti-neurofascin antibodies facilitated by non-MHC genes. *Multiple Sclerosis Journal* 2015; 21: 141-142.

Forsberg L, Johansson S, Nordin N, Hillert J, Svenningsson A, Lycke J, Burman J, Landtblom AM, Walentin F, Martin C, Nilsson P, Dahle C, Piehl F, Olsson T. A Swedish nationwide pharmaco-epidemiological and genetic study (IMSE) of the long-term safety and efficacy of dimethyl fumarate. *Multiple Sclerosis Journal* 2015; 21: 286-287.

Goris A, Pauwels I, Gustavsen MW, van Son B, Hilven K, Bos SD, Celius EG, Berg-Hansen P, Aarseth J, Myhr KM, D'Alfonso S, Barizzone N, Leone MA, Boneschi FM, Sorosina M, Liberatore G, Kockum I, Olsson T, Hillert J, Alfredsson L, Bedri SK, Hemmer B, Buck D, Berthele A, Knier B, Biberacher V, van Pesch V, Sindic C, Oturai AB, Sondergaard HB, Sellebjerg F, Jensen PEH, Comabella M, Montalban X, Perez-Boza J, Malhotra S, Lechner-Scott J, Broadley S, Slee M, Taylor B, Kermodie AG, Gourraud PA, Sawcer SJ, Andreassen BK, Dubois B, Harbo HF, Int Multiple S. Genetic variants are major determinants of CSF antibody levels in multiple sclerosis. *Brain* 2015; 138: 632-643.

Gustafsson M, Gawel DR, Alfredsson L, Baranzini S, Bjorkander J, Blomgran R, Hellberg S, Eklund D, Ernerudh J, Kockum I, Konstantinell A, Lahesmaa R, Lentini A, Liljenstrom HRI, Mattson L, Matussek A, Mellergard J, Mendez M, Olsson T, Pujana MA, Rasool O, Serra-Musach J, Stenmarker M, Tripathi S, Viitala M, Wang H, Zhang H, Nestor CE, Benson M. A validated gene regulatory network and GWAS identifies early regulators of T cell-associated diseases. *Science Translational Medicine* 2015; 7.

Gyllenberg A, Olsson LM, Acharjee B, Khademi M, Piehl F, Alfredsson L, Hillert J, Holmdahl R, Olsson T, Kockum I. NOX genes - genetic markers for severe multiple sclerosis? *Multiple Sclerosis Journal* 2015; 21: 436-437.

Hedstrom AK, Akerstedt T, Olsson T, Alfredsson L. Shift work influences multiple sclerosis risk. *Multiple Sclerosis Journal* 2015; 21: 1195-1199.

Hedstrom AK, Bomfim IL, Hillert J, Olsson T, Alfredsson L. Obesity interacts with infectious mononucleosis in risk of multiple sclerosis. *European Journal of Neurology* 2015; 22: 578-U570.

Hedstrom AK, Bomfim IL, Sondergaard HB, Oturai AB, Sellebjerg F, Gustavsen MW, Harbo HF, Obradovic D, Kockum I, Olsson T, Alfredsson L. Interaction between smoking and HLA genotype in multiple sclerosis development. *Multiple Sclerosis Journal* 2015; 21: 167-168.

Hedstrom AK, Olsson T, Alfredsson L. Smoking, organic solvents and MS susceptibility; interaction with HLA genotype. *Multiple Sclerosis Journal* 2015; 21: 36-36.

Hoffmann FS, Kuhn PH, Laurent SA, Hauck SM, Berer K, Wendlinger SA, Krumbholz M, Khademi M, Olsson T, Dreyling M, Pfister HW, Alexander T, Hiepe F, Kumpfel T, Crawford HC, Wekerle H, Hohlfeld R, Lichtenthaler SF, Meinl E. The Immunoregulator Soluble TACI Is Released by ADAM10 and Reflects B Cell Activation in Autoimmunity. *Journal of Immunology* 2015; 194: 542-552.

Hoffmann FS, Kuhn PH, Laurent SA, Hauck SM, Khademi M, Olsson T, Hohlfeld R, Lichtenthaler SF, Meinl E. Endogenous soluble TACI is elevated in multiple sclerosis patients and shares functional properties with atacicept. *Multiple Sclerosis Journal* 2015; 21: 150-150.

Johansson S, Forsberg L, Hillert J, Nilsson P, Dahle C, Svenningsson A, Lycke J, Landtblom AM, Burman J, Walentin F, Martin C, Piehl F, Olsson T. A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and efficacy of natalizumab. *Multiple Sclerosis Journal* 2015; 21: 285-286.

Johansson S, Forsberg L, Nordin N, Hillert J, Svenningsson A, Lycke J, Burman J, Landtblom AM, Walentin F, Martin C, Nilsson P, Dahle C, Piehl F, Olsson T. The IMSE 2 study: a Swedish nationwide pharmaco-epidemiological and genetic study focused on long-term safety and efficacy of fingolimod. *Multiple Sclerosis Journal* 2015; 21: 284-285.

Kotelnikova E, Bernardo-Faura M, Silberberg G, Kiani NA, Messinis D, Melas IN, Artigas L, Schwartz E, Mazo I, Masso M, Alexopoulos LG, Mas JM, Olsson T, Tegner J, Martin R, Zamora A, Paul F, Saez-Rodriguez J, Villoslada P. Signaling networks in MS: A systems-based approach to developing new pharmacological therapies. *Multiple Sclerosis Journal* 2015; 21: 138-146.

Kuhle J, Disanto G, Dobson R, Adiutori R, Bianchi L, Topping J, Bestwick JP, Meier UC, Marta M, Dalla Costa G, Runia T, Evdoshenko E, Lazareva N, Thouvenot E, Iaffaldano P, Direnzo V, Khademi M, Piehl F, Comabella M, Sombekke M, Killestein J, Hegen H, Rauch S, D'Alfonso S, Alvarez-Cermeno JC, Kleinova P, Horakova D, Roesler R, Lauda F, Llufrui S, Avsar T, Uygunoglu U, Altintas A, Saip S, Menge T, Rajda C, Bergamaschi R, Moll N, Khalil M, Marignier R, Dujmovic I, Larsson H, Malmstrom C, Scarpini E, Fenoglio C, Wergeland S, Laroni A, Annibaldi V, Romano S, Martinez AD, Carra A, Salvetti M, Uccelli A, Torkildsen O, Myhr KM, Galimberti D, Rejdak K, Lycke J, Frederiksen JL, Drulovic J, Confavreux C, Brassat D, Enzinger C, Fuchs S, Bosca I, Pelletier J, Picard C, Colombo E, Franciotta D, Derfuss T, Lindberg RLP, Yaldizli O, Vecsei L, Kieseier BC, Hartung HP, Villoslada P, Siva A, Saiz A, Tumani H, Havrdova E, Villar LM, Leone M, Barizzone N, Deisenhammer F, Teunissen C, Montalban X, Tintore M, Olsson T, Trojano M, Lehmann S, Castelnovo G, Lapin S, Hintzen R, Kappos L, Furlan R, Martinelli V, Comi G, Ramagopalan SV, Giovannoni G. Conversion from clinically isolated syndrome to multiple sclerosis: A large multicentre study. *Multiple Sclerosis Journal* 2015; 21: 1013-1024.

Laurent SA, Hoffmann FS, Kuhn PH, Cheng QY, Chu YY, Schmidt-Supprian M, Hauck SM, Schuh E, Krumbholz M, Rubsamen H, Wanggren J, Khademi M, Olsson T, Alexander T, Hiepe F, Pfister HW, Weber F, Jenne D, Wekerle H, Hohlfeld R, Lichtenthaler SF, Meinl E. gamma-secretase directly sheds the survival receptor BCMA from plasma cells. *Nature Communications* 2015; 6.

Matell H, Lycke J, Svenningsson A, Holmen C, Khademi M, Hillert J, Olsson T, Piehl F. Age-dependent effects on the treatment response of natalizumab in MS patients. *Multiple Sclerosis Journal* 2015; 21: 48-56.

Meisgen S, Hedlund M, Ambrosi A, Folkersen L, Dzikaite-Ottosson V, Ding B, Strandberg L, Biavati L, Ramskold D, Forsberg D, Bergin L, Ruhrmann S, Hamilton RM, Franco-Cereceda A, Hamsten A, Olsson T, Greene L, Eriksson P, Gemzell-Danielsson K, Salomonsson S, Kuchroo VK, Herlenius E, Kockum I, Sonesson SE, Wahren-Herlenius M, Swedish Congenital Heart B. Auxilin Is a Novel Susceptibility Gene for Congenital Heart Block Modulating Cardiac Function. *Arthritis & Rheumatology* 2015; 67.

Moutsianas L, Jostins L, Beecham AH, Dilthey AT, Xifara DK, Ban M, Shah TS, Patsopoulos NA, Alfredsson L, Anderson CA, Attfield KE, Baranzini SE, Barrett J, Binder TMC, Booth D, Buck D, Celius EG, Cotsapas C, D'Alfonso S, Dendrou CA, Donnelly P, Dubois B, Fontaine B, Fugger L, Goris A, Gourraud PA, Graetz C, Hemmer B, Hillert J, Kockum I, Leslie S, Lill CM, Martinelli-Boneschi F, Oksenberg JR, Olsson T, Oturai A, Saarela J, Sondergaard HB, Spurkland A, Taylor B, Winkelmann J, Zipp F, Haines JL, Pericak-Vance MA, Spencer CCA, Stewart G, Hafler DA, Ivinson AJ, Harbo HF, Hauser SL, De Jager PL, Compston A, McCauley JL, Sawcer S, McVean G, Int IBDGCI, Int Multiple Sclerosis G. Class II HLA interactions modulate genetic risk for multiple sclerosis. *Nature Genetics* 2015; 47: 1107-+.

Novakova L, Axelsson M, Khademi M, Zetterberg H, Blennow K, Malmstrom C, Piehl F, Olsson T, Lycke J. Relationships between CSF biomarkers of inflammation and degeneration in RRMS are also found in healthy controls. *Multiple Sclerosis Journal* 2015; 21: 353-354.

Olsson TP. Genes and lifestyle/environmental factors in MS. *Multiple Sclerosis Journal* 2015; 21: 35-35.

Ramanujam R, Hedström AK, Manouchehrinia A, Alfredsson L, Olsson T, Bottai M, Hillert J. Beneficial effect of smoking cessation on multiple sclerosis prognosis. *Multiple Sclerosis Journal* 2015; 21: 164-164.

Ramanujam R, Hedstrom AK, Manouchehrinia A, Alfredsson L, Olsson T, Bottai M, Hillert J. Effect of Smoking Cessation on Multiple Sclerosis Prognosis. *Jama Neurology* 2015; 72: 1117-1123.

Roshanisefat H, Bahmanyar S, Hillert J, Olsson T, Montgomery S. All-cause mortality following a cancer diagnosis amongst multiple sclerosis patients: a Swedish population-based cohort study. *European Journal of Neurology* 2015; 22: 1074-1080.

Sankavaram SR, Svensson MA, Olsson T, Brundin L, Johansson CB. Cell Fusion along the Anterior-Posterior Neuroaxis in Mice with Experimental Autoimmune Encephalomyelitis. *Plos One* 2015; 10.

Stahl S, Aeinehband S, Brenner P, Bhat M, Fidock MD, Khademi M, Olsson T, Engberg G, Jokinen J, Erhardt S, Piehl F. Cerebrospinal fluid kynurenines in multiple sclerosis: relation to disease course and neurocognitive symptoms. *Multiple Sclerosis Journal* 2015; 21: 351-352.

Warnke C, Olsson T, Hartung HP. PML: The Dark Side of Immunotherapy in Multiple Sclerosis. *Trends in Pharmacological Sciences* 2015; 36: 799-801.

Warnke C, Stettner M, Lehmensiek V, Dehmel T, Mausberg AK, von Geldern G, Gold R, Kumpfel T, Hohlfeld R, Maurer M, Stangel M, Straeten V, Limmroth V, Weber T, Kleinschnitz C, Wattjes MP, Svenningsson A, Olsson T, Hartung HP, Hermsen D, Tumani H,

Adams O, Kieseier BC. Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. *Multiple Sclerosis Journal* 2015; 21: 1036-1044.

Weller B, Comi G, Freedman M, Kappos L, Miller A, Olsson T, Wolinsky J, Benamor M, Truffinet P, O'Connor P. EFFECT OF TERIFLUNOMIDE ON LYMPHOCYTE AND NEUTROPHIL COUNTS. *Journal of Neurology Neurosurgery and Psychiatry* 2015; 86.

Westerlind H, Imrell K, Ramanujam R, Myhr KM, Celius EG, Harbo HF, Oturai AB, Hamsten A, Alfredsson L, Olsson T, Kockum I, Koski T, Hillert J. Identity-by-descent mapping in a Scandinavian multiple sclerosis cohort. *European Journal of Human Genetics* 2015; 23: 688-692.

Wuhrer M, Selman MHJ, McDonnell LA, Kumpfel T, Derfuss T, Khademi M, Olsson T, Hohlfeld R, Meinl E, Krumbholz M. Pro-inflammatory pattern of IgG1 Fc glycosylation in multiple sclerosis cerebrospinal fluid. *Journal of Neuroinflammation* 2015; 12.